Shopify Inc. vs Zoetis Inc — how do they compare? Shopify Inc. trades at $168.88 (market cap $211.73B), while Zoetis Inc trades at $74.42 (market cap $30.20B). The key difference: Shopify Inc. is far larger — about 7× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Shopify Inc. for 78 Days and Zoetis Inc for 70 Days on average.
| SHOP | ZTS | |
|---|---|---|
Market Cap | $211.73B | $30.20B |
Volume | 7,146,651 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $179.01 | $147.53 |
52-Week Low | $95.40 | $69.09 |
Typical Hold Time | 78 Days | 70 Days |
Enterprise Value | $206.96B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
SHOP trades at $168.69, up 1.66% today, with strong technical momentum as moving averages signal bullish sentiment. The company shows robust revenue growth from $5.6B in 2022 to $11.56B in 2025, though recent Q4 2025 EPS missed expectations. Analyst consensus remains bullish with 67% buy ratings and a $168.63 price target, while Shopify's AI innovations like Canvas and open AI agent access position it competitively against Amazon.
Outlook: Shopify's expanding merchant solutions and AI-driven commerce tools support growth, but high valuation multiples (P/E 111.19) and overbought RSI levels pose near-term risks. Investors should weigh strong fundamentals against premium pricing and competitive pressures in the e-commerce sector.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →